CP0
CP0 Brand names, CP0 Analogs
CP0 Brand Names Mixture
- No information avaliable
CP0 Chemical_Formula
C33H38N4O6
CP0 RX_link
http://www.rxlist.com/cgi/generic2/irinot.htm
CP0 fda sheet
CP0 msds (material safety sheet)
CP0 Synthesis Reference
T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)
CP0 Molecular Weight
586.678 g/mol
CP0 Melting Point
222-223 oC
CP0 H2O Solubility
Soluble
CP0 State
Solid
CP0 LogP
4.372
CP0 Dosage Forms
Solution for IM injection
CP0 Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).
CP0 Pharmacology
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).
CP0 Absorption
100%
CP0 side effects and Toxicity
Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.
CP0 Patient Information
CP0 Organisms Affected
Humans and other mammals
